News: Astex Pharmaceuticals Inc (ASTX.OQ)
ASTX.OQ on NASDAQ Stock Exchange Global Select Market
5.54USD
4:00pm EDT
5.54USD
4:00pm EDT
Price Change (% chg)
$0.31 (+5.93%)
$0.31 (+5.93%)
Prev Close
$5.23
$5.23
Open
$5.35
$5.35
Day's High
$5.59
$5.59
Day's Low
$5.28
$5.28
Volume
273,853
273,853
Avg. Vol
394,279
394,279
52-wk High
$6.94
$6.94
52-wk Low
$2.15
$2.15
Select another date:
Mon, Apr 29 2013
BRIEF-Astex Pharmaceuticals shares up 1 pct after the bell following results
NEW YORK, April 29 - Astex Pharmaceuticals Inc : * Shares were up 1 percent after the bell following the release of its results.
BRIEF-Astex Pharmaceuticals shares up 8.3 pct premarket
NEW YORK, April 3 - Astex Pharmaceuticals Inc : * Shares up 8.3 percent in premarket trading
BRIEF-GIMV sells shares of Astex, Ablynx
BRUSSELS, March 11 - Gimv NV : * Astex stake sale has 0.04 per share positive impact on Gimv * Ablynx stake reduction has 0.07 per share positive impact on Gimv
Select another date:
- Astex Pharmaceuticals, Inc. (ASTX) Management Discusses Q2 2013 Results (Webcast)
- BioPharma Catalyst Trade Pick Of The Week: Biodel
- Astex Pharmaceuticals In Focus With Catalyst In The Near Term
- Another Alzheimer's Disease Failure
- Astex Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-20-2013 03:30 PM
- 3 Horrendous Health-Care Stocks This Week
Press Releases
- Astex Pharmaceuticals Announces Results From Dose Escalation Part of SGI-110 Phase 1/2 MDS and AML Study in an Oral Presentation at ASH
- Astex Pharmaceuticals to Present at Oppenheimer Healthcare Conference
- Astex Pharmaceuticals Announces December 14th Analyst and Investor Day Agenda
- Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Results From Phase 1/2 MDS and AML Study at ASH
- Astex Pharmaceuticals to Present at Lazard Healthcare Conference
- Astex Pharmaceuticals to Present at EORTC-NCI-AACR
- Astex Pharmaceuticals Reports 2012 Third Quarter Financial Results
- Astex Pharmaceuticals, Cancer Research Technology and Newcastle University Sign Strategic Drug Discovery Alliance
- Astex Pharmaceuticals Announces Initiation of AT13387 Phase 2 Study in Non-Small Cell Lung Cancer
- Astex Pharmaceuticals to Announce 2012 Third Quarter Financial Results on October 30, 2012

